Business
Supernus Announces Third Quarter 2020 Financial Results
Q3 2020 total revenues of $155.1 million, including net product sales of $152.1 million and royalty revenues of $3.0 millionQ3 2020 operating earnings of
About this update from Supernus Pharmaceuticals, Inc.
[{"type":"text","content":"Q3 2020 total revenues of $155.1 million, including net product sales of $152.1 million and royalty revenues of $3.0 millionQ3 2020 operating earnings of $56.1 millionOn track to initiate commercial launch of SPN-812 in January 2021, if approved by the FDATopline data from the SPN-812 Phase III trial in adult ADHD patients expected in Q1 2021Submitted SPN-830 (Apomorphine infusion pump) NDA to the FDA in September 2020Increased full year 2020 net product sales guidance range of $500 million to $525 million, and operating earnings guidance range of $145 million to $160 million ROCKVILLE, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported financial results for the third quarter of 2020 and associated Company developments.\n “During the first nine months of 2020, we delivered strong product sales growth, diversified our revenue base and enhanced our long term growth with two corporate transactions” said Jack Khattar, President and CEO of Supernus. “Our employees have been hard at work in anticipation of the launch of SPN-812. Based on the efficacy and safety demonstrated in its clinical program, SPN-812 can potentially offer an important new option in the treatment of ADHD.” Commercial Update Third quarter 2020 net product sales were $152.1 million, 52% higher than the same period in 2019, driven by the addition of $40.9 million of net product sales from the acquired commercial products and $11.2 million in net product sales growth from Trokendi XR and Oxtellar XR. Net Product Sales($ in millions) Q3 2020 Q3 2019Change %Trokendi XR$82.9 $77.3 7 %Oxtellar XR28.3 22.7 25 %APOKYN34.5 — NM(1)XADAGO2.3 — NM(1)MYOBLOC4.1 — NM(1)Total$152.1 $100.0 52 % ____________(1) Fluctuation in terms of percentage change is not meaningful. Product Pipeline Update SPN-812 - Novel non-stimulant for the treatment of ADHD in children and adults The Company continues to prepare for the commercial launch of SPN-812, which is expected in January 2021, if approved by the FDA. The New Drug Application (NDA) Prescription Drug User Fee Act (PDUFA) target action date is November 8, 2020.The Company completed enrollment in the SPN-812 Phase III trial in adult patients with ADHD. T...